Key result
Extended prophylaxis with low-molecular-weight heparin significantly reduced the composite failure rate of thromboembolism, major hemorrhage, or death compared to oral anticoagulants (3.7% vs 8.3%; P=0.001).
Why the study?
Does fixed-dose subcutaneous low-molecular-weight heparin reduce the combined rate of symptomatic thromboembolic events, major hemorrhage, or death compared to adjusted-dose oral anticoagulants in patients after total hip replacement?
Population
1279 patients 3 days after total hip replacement surgery
Comparison
Fixed-dose subcutaneous low-molecular-weight… vs Adjusted-dose oral anticoagulant for a 6-week…
Design
RCT, randomly assigned
Follow-up
6 weeks
Authors
Loading...
Supports extended LMWH over oral anticoagulants after hip replacement; extends RCT evidence for LMWH in orthopedic prophylaxis.
RCT (n=1,279)
randomly assigned
Does fixed-dose subcutaneous low-molecular-weight heparin reduce the combined rate of symptomatic thromboembolic events, major hemorrhage, or death compared to adjusted-dose oral anticoagulants in patients after total hip replacement?
Absolute Event Rate: 3.7% vs 8.3%
p-value: p=0.001
Extended prophylaxis with low-molecular-weight heparin after total hip replacement is safer than oral anticoagulants, significantly reducing major bleeding without compromising efficacy against thromboembolic events.
Charles Marc Samama (2002) conducted an RCT in Total hip replacement (n=1,279). Low-molecular-weight heparin (reviparin sodium) vs. Adjusted-dose oral anticoagulant (acenocoumarol, INR 2-3) was evaluated on Failure rate (combined clinical events of a confirmed symptomatic thromboembolic event, a major hemorrhage, or death) (p=0.001). Extended prophylaxis with low-molecular-weight heparin significantly reduced the composite failure rate of thromboembolism, major hemorrhage, or death compared to oral anticoagulants (3.7% vs 8.3%; P=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: